Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)
33.34 -0.07 (-0.21%) 14:04 ET [NASDAQ]
33.32 x 15 33.34 x 186
Realtime by (Cboe BZX)
33.32 x 15 33.34 x 186
Realtime 33.65 +0.24 (+0.72%) 06:21 ET
Quote Overview for Thu, Mar 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
33.15
Day High
33.50
Open 33.44
Previous Close 33.41 33.41
Volume 1,193,758 1,193,758
Avg Vol 3,871,308 3,871,308
Stochastic %K 65.71% 65.71%
Weighted Alpha +19.37 +19.37
5-Day Change +0.64 (+1.96%) +0.64 (+1.96%)
52-Week Range 24.05 - 34.20 24.05 - 34.20
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,259,296
  • Shares Outstanding, K 576,453
  • Annual Sales, $ 2,264 M
  • Annual Income, $ 858,980 K
  • EBIT $ 1,292 M
  • EBITDA $ 1,312 M
  • 60-Month Beta 0.47
  • Price/Sales 8.51
  • Price/Cash Flow 7.96
  • Price/Book 1.90

Options Overview Details

View History
  • Implied Volatility 27.75% ( +5.38%)
  • Historical Volatility 14.98%
  • IV Percentile 34%
  • IV Rank 34.27%
  • IV High 58.59% on 06/13/24
  • IV Low 11.67% on 08/19/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 38
  • Volume Avg (30-Day) 598
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 33,979
  • Open Int (30-Day) 31,401

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 1.02
  • Number of Estimates 3
  • High Estimate 1.04
  • Low Estimate 1.00
  • Prior Year 0.98
  • Growth Rate Est. (year over year) +4.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.00 +4.12%
on 03/12/25
Period Open: 33.33
34.20 -2.57%
on 02/24/25
-0.01 (-0.03%)
since 02/20/25
3-Month
24.46 +36.22%
on 12/23/24
Period Open: 24.92
34.20 -2.57%
on 02/24/25
+8.40 (+33.71%)
since 12/20/24
52-Week
24.05 +38.54%
on 12/19/24
Period Open: 30.41
34.20 -2.57%
on 02/24/25
+2.91 (+9.57%)
since 03/20/24

Most Recent Stories

More News
3 Value Stocks in Hot Water

3 Value Stocks in Hot Water

RPRX : 33.34 (-0.21%)
DLTR : 65.38 (+1.68%)
SCSC : 36.72 (-1.21%)
1 Stock Under $50 with Exciting Potential and 2 to Ignore

1 Stock Under $50 with Exciting Potential and 2 to Ignore

RPRX : 33.34 (-0.21%)
KRT : 28.92 (-0.92%)
GXO : 40.89 (+0.12%)
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

CORT : 57.89 (-0.19%)
RPRX : 33.34 (-0.21%)
SUPN : 32.19 (+0.50%)
OGN : 15.55 (-1.52%)
ZTS : 162.74 (-0.62%)
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference

RPRX : 33.34 (-0.21%)
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

These biotech companies’ strategic advancements are setting them up for long-term success.

RPRX : 33.34 (-0.21%)
JNJ : 162.50 (-0.30%)
VRTX : 506.99 (-1.08%)
SNDX : 14.11 (+7.55%)
ABBV : 211.36 (-0.42%)
GERN : 1.7200 (+1.18%)
RHHBY : 43.2800 (-0.18%)
PFE : 26.08 (-0.50%)
NTLA : 8.81 (-5.27%)
BMY : 59.88 (-0.33%)
BIIB : 141.84 (+0.29%)
Royalty Pharma Announces R&D Funding Collaboration With Biogen

RPRX : 33.34 (-0.21%)
2 ‘Strong Buy’ Growth Stocks Poised for 141% to 193% Gains, According to Wall Street

The recent advancements in their pipelines imply high growth potential in the coming years.

ZVRA : 7.97 (+0.25%)
RPRX : 33.34 (-0.21%)
SNDX : 14.11 (+7.55%)
INCY : 60.44 (+0.17%)
Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates

Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates

RPRX : 33.34 (-0.21%)
Royalty Pharma Reports Q4 and Full Year 2024 Results

RPRX : 33.34 (-0.21%)
Royalty Pharma Earnings: What To Look For From RPRX

Royalty Pharma Earnings: What To Look For From RPRX

RPRX : 33.34 (-0.21%)
PFE : 26.08 (-0.50%)
BMY : 59.88 (-0.33%)
Q3 Earnings Roundup: RingCentral (NYSE:RNG) And The Rest Of The Video Conferencing Segment

Q3 Earnings Roundup: RingCentral (NYSE:RNG) And The Rest Of The Video Conferencing Segment

ZM : 76.25 (-0.01%)
RNG : 27.06 (-0.55%)
FIVN : 29.74 (-1.56%)
EGHT : 2.20 (-1.79%)
Q3 Video Conferencing Earnings: Five9 (NASDAQ:FIVN) Earns Top Marks

Q3 Video Conferencing Earnings: Five9 (NASDAQ:FIVN) Earns Top Marks

ZM : 76.25 (-0.01%)
RNG : 27.06 (-0.55%)
FIVN : 29.74 (-1.56%)
EGHT : 2.20 (-1.79%)
The Zacks Analyst Blog Highlights Five9, Innodata, AudioEye, UiPath and BigBear.ai

For Immediate ReleaseChicago, IL – December 17, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...

PATH : 10.86 (+0.56%)
BBAI : 2.99 (-3.86%)
INOD : 43.12 (-1.84%)
FIVN : 29.74 (-1.56%)
AEYE : 11.51 (-1.62%)
Buy These 5 Small & Mid-Sized AI Stocks Set to Flourish in 2025

Wall Street witnessed an astonishing bull run in the past 24 months. The major driver of last year and this year’s rally has been the globally booming artificial intelligence (AI), especially generative...

PATH : 10.86 (+0.56%)
BBAI : 2.99 (-3.86%)
INOD : 43.12 (-1.84%)
FIVN : 29.74 (-1.56%)
AEYE : 11.51 (-1.62%)
A Look Back at Video Conferencing Stocks’ Q3 Earnings: 8x8 (NASDAQ:EGHT) Vs The Rest Of The Pack

A Look Back at Video Conferencing Stocks’ Q3 Earnings: 8x8 (NASDAQ:EGHT) Vs The Rest Of The Pack

ZM : 76.25 (-0.01%)
RNG : 27.06 (-0.55%)
FIVN : 29.74 (-1.56%)
EGHT : 2.20 (-1.79%)
Insider Sale: Chief Executive Officer of $FIVN (FIVN) Sells 12,594 Shares

Michael Burkland, the Chief Executive Officer of $FIVN ($FIVN), sold 12,594 shares of the company on 12-03-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

FIVN : 29.74 (-1.56%)
Earnings To Watch: Box (BOX) Reports Q3 Results Tomorrow

Earnings To Watch: Box (BOX) Reports Q3 Results Tomorrow

BOX : 30.32 (-1.65%)
DBX : 26.49 (-0.97%)
FIVN : 29.74 (-1.56%)
Best Growth Stocks to Buy for November 27th

The Greenbrier Companies, Inc. GBX: This railroad freight car equipment company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 18.2%...

PBI : 9.36 (-1.37%)
FIVN : 29.74 (-1.56%)
GBX : 54.85 (-0.16%)
Three Reasons Why FIVN is Risky and One Stock to Buy Instead

Three Reasons Why FIVN is Risky and One Stock to Buy Instead

FIX : 359.63 (+0.59%)
FIVN : 29.74 (-1.56%)
NET : 118.27 (+0.59%)
Box Shares Rise 39% Year to Date: How Should Investors Play the Stock?

Box, Inc. BOX shares have surged 39.2% year to date, outperforming the Zacks Computer and Technology sector’s appreciation of 27.5% and the Zacks Internet Software industry’s return of 31.2%.BOX shares...

BOX : 30.32 (-1.65%)
BL : 50.00 (-0.32%)
FIVN : 29.74 (-1.56%)
EGHT : 2.20 (-1.79%)
Q3 Earnings Roundup: RingCentral (NYSE:RNG) And The Rest Of The Video Conferencing Segment

Q3 Earnings Roundup: RingCentral (NYSE:RNG) And The Rest Of The Video Conferencing Segment

ZM : 76.25 (-0.01%)
RNG : 27.06 (-0.55%)
FIVN : 29.74 (-1.56%)
EGHT : 2.20 (-1.79%)
Q3 Video Conferencing Earnings: Five9 (NASDAQ:FIVN) Earns Top Marks

Q3 Video Conferencing Earnings: Five9 (NASDAQ:FIVN) Earns Top Marks

ZM : 76.25 (-0.01%)
RNG : 27.06 (-0.55%)
FIVN : 29.74 (-1.56%)
EGHT : 2.20 (-1.79%)
The Zacks Analyst Blog Highlights Five9, Innodata, AudioEye, UiPath and BigBear.ai

For Immediate ReleaseChicago, IL – December 17, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...

PATH : 10.86 (+0.56%)
BBAI : 2.99 (-3.86%)
INOD : 43.12 (-1.84%)
FIVN : 29.74 (-1.56%)
AEYE : 11.51 (-1.62%)
Buy These 5 Small & Mid-Sized AI Stocks Set to Flourish in 2025

Wall Street witnessed an astonishing bull run in the past 24 months. The major driver of last year and this year’s rally has been the globally booming artificial intelligence (AI), especially generative...

PATH : 10.86 (+0.56%)
BBAI : 2.99 (-3.86%)
INOD : 43.12 (-1.84%)
FIVN : 29.74 (-1.56%)
AEYE : 11.51 (-1.62%)
A Look Back at Video Conferencing Stocks’ Q3 Earnings: 8x8 (NASDAQ:EGHT) Vs The Rest Of The Pack

A Look Back at Video Conferencing Stocks’ Q3 Earnings: 8x8 (NASDAQ:EGHT) Vs The Rest Of The Pack

ZM : 76.25 (-0.01%)
RNG : 27.06 (-0.55%)
FIVN : 29.74 (-1.56%)
EGHT : 2.20 (-1.79%)
Insider Sale: Chief Executive Officer of $FIVN (FIVN) Sells 12,594 Shares

Michael Burkland, the Chief Executive Officer of $FIVN ($FIVN), sold 12,594 shares of the company on 12-03-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

FIVN : 29.74 (-1.56%)
Earnings To Watch: Box (BOX) Reports Q3 Results Tomorrow

Earnings To Watch: Box (BOX) Reports Q3 Results Tomorrow

BOX : 30.32 (-1.65%)
DBX : 26.49 (-0.97%)
FIVN : 29.74 (-1.56%)
Best Growth Stocks to Buy for November 27th

The Greenbrier Companies, Inc. GBX: This railroad freight car equipment company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 18.2%...

PBI : 9.36 (-1.37%)
FIVN : 29.74 (-1.56%)
GBX : 54.85 (-0.16%)
Three Reasons Why FIVN is Risky and One Stock to Buy Instead

Three Reasons Why FIVN is Risky and One Stock to Buy Instead

FIX : 359.63 (+0.59%)
FIVN : 29.74 (-1.56%)
NET : 118.27 (+0.59%)
Box Shares Rise 39% Year to Date: How Should Investors Play the Stock?

Box, Inc. BOX shares have surged 39.2% year to date, outperforming the Zacks Computer and Technology sector’s appreciation of 27.5% and the Zacks Internet Software industry’s return of 31.2%.BOX shares...

BOX : 30.32 (-1.65%)
BL : 50.00 (-0.32%)
FIVN : 29.74 (-1.56%)
EGHT : 2.20 (-1.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 33.91
2nd Resistance Point 33.70
1st Resistance Point 33.56
Last Price 33.34
1st Support Level 33.21
2nd Support Level 33.00
3rd Support Level 32.86

See More

52-Week High 34.20
Last Price 33.34
Fibonacci 61.8% 30.32
Fibonacci 50% 29.13
Fibonacci 38.2% 27.93
52-Week Low 24.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.